Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria

Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria

Abstract Background Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) have improved the treatment of renal anemia, especially in patients resistant to erythropoiesis-stimulating agents (ESAs). HIF facilitates maintain gut microbiota homeostasis, which plays an important role in infla...

Full description

Bibliographic Details
Main Authors: Xiu-Nan Zhao, Shu-Xin Liu, Zhen-Zhen Wang, Shuang Zhang, Lian-Lian You
Format: Article
Language:English
Published: BMC 2023-07-01
Series:European Journal of Medical Research
Subjects:
Gut microbiota
Hemodialysis
Renal anemia
Erythropoiesis-stimulating agent
Drug resistance
Roxadustat
Online Access:https://doi.org/10.1186/s40001-023-01179-3

Internet

https://doi.org/10.1186/s40001-023-01179-3

Similar Items